Table 2.
Representative transdermal drugs in clinical development
| Drug | Company | Indication | Clinical phase | Delivery technology |
|---|---|---|---|---|
| AB-1001 | Abeille | Nausea and vomiting | Phase 3 | Passive |
| acyclovir | Transport | Herpes labialis | Phase 2 | Iontophoresis |
| buprenorphine | Purdue Pharma | Pain | Phase 3* | Passive |
| fertility hormone | Vyteris / Ferring | Female infertility | Phase 1 | Iontophoresis |
| granisetron | Prostrakan | Nausea and vomiting | Pre-registration | Passive |
| heat-labile enterotoxin of E. coli. | Iomai | Travelers’ diarrhea | Phase 2 | Skin abrasion |
| human growth hormone | TransPharma / Teva | Growth hormone deficiency | Phase 1 | Thermal ablation |
| influenza vaccine | Becton Dickinson / Sanofi-Pasteur | Influenza prophylaxis | Pre-registration | Microneedles |
| insulin | Altea | Diabetes mellitus | Phase 1 | Thermal ablation |
| insulin | Phosphagenics | Diabetes mellitus | Phase 2 | Vesicular carrier |
| ketoprofen | ZARS | Osteoarthritis | Phase 3 | Heat enhancement |
| parathyroid hormone (1–34) | Zosano | Osteoporosis | Phase 2 | Microneedles |
| sufentanil | Durect / Endo | Chronic pain | Phase 2 | Passive |
| testosterone | Acrux / VIVUS | Female sexual dysfunction | Phase 2 | Metered dose transdermal spray |
| testosterone | MacroChem | Male hypogonadism | Phase 2 | Chemical enhancer (SEPA) |
| testosterone | Procter & Gamble / Watson | Hypoactive sexual desire disorder | Pre-registration* | Passive |
| triamcinolone acetonide | Echo Therapeutics | Dermatoses | Pre-registration | Chemical enhancer (AzoneTS) |
*
Already marketed outside of USA